BlackRock Health Sciences Term Trust (NYSE:BMEZ) to Issue Dividend of $0.18

BlackRock Health Sciences Term Trust (NYSE:BMEZ) declared a dividend on Thursday, January 2nd,NASDAQ Dividends reports. Shareholders of record on Wednesday, January 15th will be given a dividend of 0.1782 per share on Friday, January 31st. The ex-dividend date of this dividend is Wednesday, January 15th.

BlackRock Health Sciences Term Trust has increased its dividend by an average of 20.7% per year over the last three years.

BlackRock Health Sciences Term Trust Stock Performance

Shares of NYSE BMEZ traded up $0.52 during mid-day trading on Friday, reaching $15.00. The company had a trading volume of 722,833 shares, compared to its average volume of 513,116. The company has a 50-day moving average price of $15.33 and a two-hundred day moving average price of $15.56. BlackRock Health Sciences Term Trust has a 1-year low of $14.27 and a 1-year high of $16.59.

Insider Buying and Selling at BlackRock Health Sciences Term Trust

In other BlackRock Health Sciences Term Trust news, major shareholder Saba Capital Management, L.P. bought 29,795 shares of the firm’s stock in a transaction on Wednesday, October 16th. The stock was bought at an average cost of $15.81 per share, with a total value of $471,058.95. Following the completion of the transaction, the insider now directly owns 20,750,913 shares of the company’s stock, valued at approximately $328,071,934.53. The trade was a 0.14 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

About BlackRock Health Sciences Term Trust

BlackRock Health Sciences Trust II’s (BMEZ) (the ‘Trust’) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries.